comparemela.com

Latest Breaking News On - Heidelberg pharma research - Page 5 : comparemela.com

Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure

DGAP-News: Heidelberg Pharma AG / Key word(s): Corporate ActionHeidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure 30.08.2022 / 17:41 CET/CESTThe issuer is solely responsible for the content of this announcement.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE.

Baden wübergSylvia wimmerHeidelberg pharmaMc servicesFrankfurt stock exchangeUnited statesDistribution servicesBaader bankRegister at mannheim local courtGmbh coHuadong medicine co ltdCorporate communicationsHeidelberg pharma research gmbCorporate actionFrom capital measureFrom capital

Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure

DGAP-News: Heidelberg Pharma AG / Key word: Corporate Action Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure 30.08.2022 / 17:41 CET/CEST The issuer.

Baden wübergSylvia wimmerHeidelberg pharmaMc servicesFrankfurt stock exchangeUnited statesBaader bankRegister at mannheim local courtHuadong medicine co ltdGmbh coCorporate communicationsHeidelberg pharma research gmbFrom capitalHuadong investmentCommercial registerMannheim local court

DGAP-News: Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million

DGAP-News: Heidelberg Pharma AG / Key word(s): Corporate Action Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million .

Sylvia wimmerHeidelberg pharmaGerman federal financial supervisory authority bafinMc servicesFrankfurt stock exchangeUnited statesBaader bankHuadong medicine co ltdGmbh coCorporate communicationsHeidelberg pharma research gmbRights issueManagement boardSupervisory boardGerman federal financial supervisory authorityAuthorized capital

Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million

12.08.2022 Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million | Heidelberg Pharma AG | News | Nachricht | Mitteilung

Sylvia wimmerHeidelberg pharmaGerman federal financial supervisory authority bafinMc servicesFrankfurt stock exchangeUnited statesBaader bankHuadong medicine co ltdGmbh coCorporate communicationsHeidelberg pharma research gmbRights issueManagement boardSupervisory boardGerman federal financial supervisory authorityAuthorized capital

Investegate |Heidelberg Pharma AG Announcements | Heidelberg Pharma AG: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate

Investegate announcements from Heidelberg Pharma AG, Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate

Sylvia wimmerChiome bioscienceHeidelberg pharma amanitinHeidelberg pharmaMc servicesAgreement for the developmentChiome bioscience incFrankfurt stock exchangeHeidelberg pharma research gmbDistribution servicesChiome bioscience sign exclusiveTarget specific researchOption agreementAntibody drugPharma research gmbhHeidelberg pharma research

vimarsana © 2020. All Rights Reserved.